Stocklytics Platform
Asset logo for symbol BSX
Boston Scientific
BSX75
$86.42arrow_drop_down0.66%-$0.57
High Quality
S&P500
Asset logo for symbol BSX
BSX75

$86.42

arrow_drop_down0.66%

Performance History

Chart placeholder
Key Stats
Open$87.31
Prev. Close$87.00
EPS1.23
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
LOWHIGH
Day Range86.42
87.48
52 Week Range48.35
85.25
Ratios
EPS1.23

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•
•

About Boston Scientific (BSX)

Boston Scientific Corp (BSX) is a leading global medical technology company that develops and manufactures innovative devices used in a wide range of medical procedures. The company's mission is to improve patient outcomes and quality of life by providing physicians with advanced tools and technologies. With a market cap of over $50 billion, Boston Scientific is a major player in the healthcare industry. The company's stock price history has shown steady growth over the years, reflecting its strong performance and market demand for its products.
One key factor investors consider when evaluating a stock is its price-to-earnings growth (PEG) ratio. Boston Scientific Corp has a PEG ratio of 1.85, indicating that the stock is reasonably priced relative to its expected earnings growth. This ratio is calculated by dividing the stock's P/E ratio by its projected earnings growth rate. A PEG ratio below 1.0 is generally considered favorable, as it suggests the stock may be undervalued. In comparison to its industry peers, Boston Scientific Corp has a competitive PEG ratio, demonstrating its potential for future growth.
Websitecall_made
Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Michael F. Mahoney
Headquarters
Marlborough
Employees
45000
Exchange
NYSE
add Boston Scientific to watchlist

Keep an eye on Boston Scientific

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is Boston Scientific's (BSX) price per share?

The current price per share for Boston Scientific (BSX) is $86.42. The stock has seen a price change of -$0.58 recently, indicating a -0.66% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for Boston Scientific (BSX)?

For Boston Scientific (BSX), the 52-week high is $85.25, which is -1.35% from the current price. The 52-week low is $48.35, the current price is 78.74% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is Boston Scientific (BSX) a growth stock?

Boston Scientific (BSX) has shown an average price growth of -1.93% over the past three years. It has received a score of 82 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Boston Scientific as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is Boston Scientific (BSX) stock price performance year to date (YTD)?

As of the latest data, Boston Scientific (BSX) has a year-to-date price change of 49.41%. Over the past month, the stock has experienced a price change of 3.48%. Over the last three months, the change has been 10.6%. Over the past six months, the figure is 26.86%. Looking at a longer horizon, the five-year price change stands at 126.35%.
help

Is Boston Scientific (BSX) a profitable company?

Boston Scientific (BSX) has a net income of $1.59B, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 69.49% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 19.39% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $14.24B, with a revenue growth rate of 12.29%, providing insight into the company's sales performance and growth. The gross profit is $9.9B. Operating income is noted at $2.34B. Furthermore, the EBITDA is $4B.
help

What is the market capitalization of Boston Scientific (BSX)?

Boston Scientific (BSX) has a market capitalization of $127.78B. The average daily trading volume is 86.75, indicating the stock's liquidity and investor engagement.

News

AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery
AMN HEALTHCARE SERVICES
WORKWISE
HEALTHCARE DELIVERY
WORKFORCE MANAGEMENT
Oct 8, 2024

AMN Stock Down Despite WorkWise Launch to Enhance Healthcare Delivery

Pancreatic and Bile Duct Stone Management Market is Growing at 4.5% CAGR Through 2034 | Fact.MR Report
PANCREATIC STONES
BILE DUCT STONES
MEDICAL DEVICES
MINIMALLY INVASIVE PROCEDURES
Oct 7, 2024

Pancreatic and Bile Duct Stone Management Market is Growing at 4.5% CAGR Through 2034 | Fact.MR Report

U.S. Defibrillator Market Size, Share & Trends Analysis 2024-2030: Government Initiatives and Healthcare Organization Support Drive Adoption - Medtronic, Abbott, and Boston Scientific Lead
DEFIBRILLATOR
CARDIOVASCULAR DISEASE
HEALTHCARE
GOVERNMENT INITIATIVES
Oct 4, 2024

U.S. Defibrillator Market Size, Share & Trends Analysis 2024-2030: Government Initiatives and Healthcare Organization Support Drive Adoption - Medtronic, Abbott, and Boston Scientific Lead

Spinal Fusion Stimulator Market is Projected to Reach a CAGR of 6.3% Through 2034 | Fact.MR
SPINAL FUSION STIMULATOR
CHRONIC PAIN
MEDICAL DEVICES
SURGICAL VOLUME
MARKET GROWTH
Sep 23, 2024

Spinal Fusion Stimulator Market is Projected to Reach a CAGR of 6.3% Through 2034 | Fact.MR

Heart Failure Monitoring Systems Market Growth to Reach US$ 24,612.2 Million at a CAGR of 5.7% by 2034 | Fact.MR
HEART FAILURE MONITORING SYSTEMS
CARDIOVASCULAR DISEASES
MEDICAL DEVICES
Sep 19, 2024

Heart Failure Monitoring Systems Market Growth to Reach US$ 24,612.2 Million at a CAGR of 5.7% by 2034 | Fact.MR

Global Electrotherapy System Research Report 2024: A $1.65 Billion Market by 2030 - TENS Segment Dominates as Demand for Chronic Pain Management Grows
ELECTROTHERAPY
TENS
CHRONIC PAIN
MARKET GROWTH
TECHNOLOGY ADVANCEMENTS
Sep 17, 2024

Global Electrotherapy System Research Report 2024: A $1.65 Billion Market by 2030 - TENS Segment Dominates as Demand for Chronic Pain Management Grows

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level